Cardinal Health stock (US14149Y1082): Q4 revenue beats estimates by 1.2%

Cardinal Health reported Q4 CY2025 revenue of $65.63 billion, surpassing analyst expectations by 1.2%, with adjusted EPS of $2.63 beating forecasts by 11.2%. Management raised full-year guidance.

Cardinal Health, a major healthcare distributor, released its Q4 CY2025 results showing revenue of $65.63 billion, up 18.8% year-over-year and exceeding Wall Street estimates of $64.85 billion by 1.2%, according to StockStory as of May 2026. Adjusted EPS came in at $2.63, 11.2% above the $2.37 consensus, while adjusted EBITDA reached $1.03 billion, beating expectations by 10.7%. The company also raised its full-year adjusted EPS guidance to a midpoint of $10.25, up 5.1%.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Cardinal Health
• Sector/industry: Healthcare distribution
• Headquarters/country: United States
• Core markets: US, North America
• Key revenue drivers: Pharmaceuticals, medical products
• Home exchange/listing venue: NYSE (CAH)
• Trading currency: USD

Cardinal Health Inc.: core business model

Cardinal Health Inc. operates as a leading distributor of pharmaceuticals and medical products in the US market, serving hospitals, pharmacies, and healthcare providers. The company manages supply chains for brand-name and generic drugs, along with medical-surgical products and laboratory equipment. Its business spans two main segments: Pharmaceutical and Medical, with the former driving the majority of revenue through distribution services.

With a market capitalization of $49.15 billion as reported in Q4 CY2025 results published in May 2026 per StockStory as of May 2026, Cardinal Health holds a significant position in the US healthcare logistics sector. The stock traded at $206.02 per share post-earnings, reflecting a 19x forward P/E ratio.

Main revenue and product drivers for Cardinal Health Inc.

Pharmaceutical distribution remains the core revenue driver, fueled by demand for both branded and generic drugs amid rising US healthcare spending. In Q4 CY2025, revenue growth of 18.8% year-over-year highlighted strong execution in this area, with free cash flow improving to $555 million from a negative $499 million prior year, according to the same source.

Medical products, including gloves, apparel, and devices, contribute through manufacturer partnerships. Operating margins held steady at 1.1%, aligning with the prior year despite scale expansion. These drivers position Cardinal Health as a key player for US investors tracking healthcare supply chains.

Industry trends and competitive position

The US healthcare distribution sector faces pressures from drug pricing reforms and supply chain disruptions, yet Cardinal Health benefits from its scale and nationwide network. Competitors like Cencora (COR) and McKesson (MCK) reported similar quarterly growth, with COR at 5.5% revenue increase in fiscal Q1 2026 per Tickeron data.

Cardinal Health's raised guidance signals confidence in navigating these trends, particularly in the US market where it derives substantial exposure.

Conclusion

Cardinal Health's Q4 results demonstrated robust revenue growth and earnings beats, coupled with upward guidance revision, underscoring operational strength in healthcare distribution. The stock's valuation at 19x forward P/E and analyst price targets around $249.60 suggest market optimism. US investors may note its pivotal role in domestic supply chains amid ongoing sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.